Antonio Iavarone

Antonio Iavarone

Auto-generated profile, based on publicly available information

Antonio Iavarone

Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Cell
Verified
Journal Article
Open access
FSFrancisco Sanchez-Vega
Francisco Sanchez-Vega
MMMarco Mina
Marco Mina
JAJoshua Armenia
Joshua Armenia
WCWalid K. Chatila
Walid K. Chatila
ALAugustin Luna
Augustin Luna
AMArmaz Mariamidze
Armaz Mariamidze
Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and cell growth are common hallmarks of cancer, but the extent, mechanisms, and co-occurrence of alterations in these pathways differ between individual tumors and tumor types. Using mutations, copy-number changes, mRNA expression, gene fusions and DNA methylation in 9,125 tumors profiled by The Cancer Genome Atlas (TCGA), we analyzed the mechanisms and patterns of somatic alterations in ten canonical pathways: cell cycle, Hippo, Myc, Notch, Nrf2, PI-3-Kinase/Akt, RTK-RAS, TGFβ signaling, p53 and β-catenin/Wnt. We charted the detailed landscape of pathway alterations in 33 cancer types, stratified into 64 subtypes, and identified patterns of co-occurrence and mutual exclusivity. Eighty-nine percent of tumors had at least one driver alteration in these pathways, and 57% percent of tumors had at least one alteration potentially targetable by currently available drugs. Thirty percent of tumors had multiple targetable alterations, indicating opportunities for combination therapy.

1 January 2016 in Cell
Verified
Journal Article
Closed access
MCMichele Ceccarelli
Michele Ceccarelli
FBFloris Barthel
Floris Barthel
TMTathiane M. Malta
Tathiane M. Malta
TSThais S. Sabedot
Thais S. Sabedot
SSSofie Reda Salama
Sofie Reda Salama
EZErik Zmuda
Erik Zmuda

23 December 2009 in Nature
Verified
Journal Article
Open access
PDF file
MCMaria Stella Carro
Maria Stella Carro
WLWei Keat Lim
Wei Keat Lim
MAMariano Javier Alvarez
Mariano Javier Alvarez
RBRobert J. Bollo
Robert J. Bollo
XZXudong Zhao
Xudong Zhao
AIAntonio Iavarone
Antonio Iavarone
The inference of transcriptional networks that regulate transitions into physiological or pathological cellular states remains a central challenge in systems biology. A mesenchymal phenotype is the hallmark of tumour aggressiveness in human malignant glioma, but the regulatory programs responsible for implementing the associated molecular signature are largely unknown. Here we show that reverse-engineering and an unbiased interrogation of a glioma-specific regulatory network reveal the transcriptional module that activates expression of mesenchymal genes in malignant glioma. Two transcription factors (C/EBPβ and STAT3) emerge as synergistic initiators and master regulators of mesenchymal transformation. Ectopic co-expression of C/EBPβ and STAT3 reprograms neural stem cells along the aberrant mesenchymal lineage, whereas elimination of the two factors in glioma cells leads to collapse of the mesenchymal signature and reduces tumour aggressiveness. In human glioma, expression of C/EBPβ and STAT3 correlates with mesenchymal differentiation and predicts poor clinical outcome. These results show that the activation of a small regulatory module is necessary and sufficient to initiate and maintain an aberrant phenotypic state in cancer cells.

7 September 2012 in Science
Verified
Journal Article
Closed access
PDF file
DSDevendra Singh
Devendra Singh
JCJoseph Minhow Chan
Joseph Minhow Chan
PZPietro Zoppoli
Pietro Zoppoli
FNFrancesco Niola
Francesco Niola
RSRyan Sullivan
Ryan Sullivan
AIAntonio Iavarone
Antonio Iavarone
Oncogenic TACC-tics: Human cancers exhibit many types of genomic rearrangements—including some that juxtapose sequences from two unrelated genes—thereby creating fusion proteins with oncogenic activity. Functional analysis of these fusion genes can provide mechanistic insights into tumorigenesis and potentially lead to effective drugs, as famously illustrated by the BCR-ABL gene in chronic myelogenous leukemia. Singh et al. (p. 1231 , published online 26 July) identify and characterize a fusion gene present in 3% of human glioblastomas, a deadly brain cancer. In the resultant fusion protein, the tyrosine kinase region of the fibroblast growth factor receptor (FGFR) is joined to a domain from a transforming acidic coiled-coil (TACC) protein. The TACC-FGFR protein is oncogenic, shows unregulated kinase activity, localizes to the mitotic spindle, and disrupts chromosome segregation. In mice, FGFR inhibitors slowed the growth of tumors driven by the TACC-FGFR gene, suggesting that a subset of glioblastoma patients may benefit from these types of drugs.

6 June 2016 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JWJiguang Wang
Jiguang Wang
ECEmanuela Cazzato
Emanuela Cazzato
ELErik Ladewig
Erik Ladewig
VFVeronique Frattini
Veronique Frattini
DRDaniel Ian Scholes Rosenbloom
Daniel Ian Scholes Rosenbloom
RRRaul Rabadan
Raul Rabadan

11 May 2018 in Science
Verified
Journal Article
Closed access
PDF file
RPRalph B. Puchalski
Ralph B. Puchalski
NSNameeta Shah
Nameeta Shah
JMJeremy Miller
Jeremy Miller
RDRachel Dalley
Rachel Dalley
SNSteve R. Nomura
Steve R. Nomura
GFGreg D. Foltz
Greg D. Foltz
Anatomically correct tumor genomics: Glioblastoma is the most lethal form of human brain cancer. The genomic alterations and gene expression profiles characterizing this tumor type have been widely studied. Puchalski et al. created the Ivy Glioblastoma Atlas, a freely available online resource for the research community. The atlas, a collaborative effort between bioinformaticians and pathologists, maps molecular features of glioblastomas, such as transcriptional signatures, to histologically defined anatomical regions of the tumors. The relationships identified in this atlas, in conjunction with associated databases of clinical and genomic information, could provide new insights into the pathogenesis, diagnosis, and treatment of glioblastoma. Science , this issue p. 660